Assembly Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Assembly Biosciences
ASMB Stock  USD 11.26  0.67  6.33%   
Assembly Biosciences financial statements provide useful quarterly and yearly information to potential Assembly Biosciences investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Assembly Biosciences financial statements helps investors assess Assembly Biosciences' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Assembly Biosciences' valuation are summarized below:
Gross Profit
-24.3 M
Profit Margin
(1.44)
Market Capitalization
67.3 M
Enterprise Value Revenue
0.4145
Revenue
28.3 M
We have found one hundred twenty available fundamental signals for Assembly Biosciences, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Assembly Biosciences prevailing market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. As of March 19, 2025, Market Cap is expected to decline to about 38.5 M. In addition to that, Enterprise Value is expected to decline to about 23.5 M

Assembly Biosciences Total Revenue

11.2 Million

Check Assembly Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Assembly Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 543.4 K, Interest Expense of 544.1 K or Selling General Administrative of 17.7 M, as well as many indicators such as Price To Sales Ratio of 6.87, Dividend Yield of 0.0 or PTB Ratio of 0.94. Assembly financial statements analysis is a perfect complement when working with Assembly Biosciences Valuation or Volatility modules.
  
Check out the analysis of Assembly Biosciences Correlation against competitors.
For information on how to trade Assembly Stock refer to our How to Trade Assembly Stock guide.

Assembly Biosciences Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets130.2 M157.3 M135.4 M
Slightly volatile
Short and Long Term Debt Total2 M2.1 M8.9 M
Slightly volatile
Other Current Liabilities5 M7.6 M5.2 M
Slightly volatile
Total Current Liabilities47.4 M45.1 M16.8 M
Slightly volatile
Property Plant And Equipment Net3 M3.1 M2.9 M
Slightly volatile
Accounts Payable394.2 K414.9 K2.1 M
Slightly volatile
Cash36.5 M22.8 M36 M
Slightly volatile
Non Current Assets Total3.3 M3.5 M25.7 M
Very volatile
Non Currrent Assets Other340.9 K358.8 K968.8 K
Pretty Stable
Cash And Short Term Investments99.4 M149.8 M105 M
Slightly volatile
Common Stock Total Equity59.2 K56.4 K29.1 K
Slightly volatile
Common Stock Shares Outstanding5 M5.3 M12.3 M
Pretty Stable
Liabilities And Stockholders Equity130.2 M157.3 M135.4 M
Slightly volatile
Non Current Liabilities Total62.5 M50.9 M136.3 M
Slightly volatile
Other Current Assets8.1 M7.7 M4.1 M
Slightly volatile
Other Stockholder Equity998.5 M951 M492.3 M
Slightly volatile
Total Liabilities115.6 M110.1 M40.6 M
Slightly volatile
Property Plant And Equipment Gross3 M3.4 M2.9 M
Slightly volatile
Total Current Assets102.4 M153.9 M108.2 M
Slightly volatile
Short Term Debt1.3 M1.4 M3.3 M
Pretty Stable
Common Stock5.5 K5.8 K19.8 K
Pretty Stable
Property Plant Equipment1 M854.5 K998.5 K
Slightly volatile
Net Tangible Assets107.5 M95.1 M93.3 M
Slightly volatile
Capital Surpluse975.6 M929.1 M494.8 M
Slightly volatile
Other Liabilities2.3 M2.5 M13.8 M
Pretty Stable
Current Deferred Revenue37.3 M35.6 M10.7 M
Slightly volatile
Net Receivables36.8 K38.7 K1.7 M
Slightly volatile
Net Invested Capital35.1 M37 M124.6 M
Pretty Stable
Net Working Capital124 M85.1 M128.9 M
Very volatile
Capital Stock4.3 K4.5 K25.1 K
Pretty Stable
Capital Lease Obligations2 M2.1 M9.3 M
Slightly volatile

Assembly Biosciences Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization543.4 K517.5 K293.6 K
Slightly volatile
Selling General Administrative17.7 M26.3 M18.6 M
Slightly volatile
Other Operating Expenses61 M82.6 M63.9 M
Slightly volatile
Research Development43.3 M56.2 M45.3 M
Slightly volatile
Total Operating Expenses61 M82.6 M63.9 M
Slightly volatile
Net Interest Income1.6 M2.2 M1.8 M
Pretty Stable
Interest Income1.6 M2.2 M1.8 M
Pretty Stable
Reconciled Depreciation550.2 K563.5 K384.3 K
Slightly volatile
Extraordinary Items6.9 M7.7 M8.4 M
Slightly volatile
Selling And Marketing Expenses360 K405 K441.6 K
Slightly volatile

Assembly Biosciences Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation9 M5.9 M9 M
Slightly volatile
Begin Period Cash Flow35.3 M60.3 M38.1 M
Slightly volatile
Other Cashflows From Financing Activities110.3 K116.1 K16.6 M
Pretty Stable
Depreciation543.4 K517.5 K293.6 K
Slightly volatile
Capital Expenditures278.6 K293.2 K586.4 K
Slightly volatile
Total Cash From Financing Activities15.1 M15.9 M40.7 M
Very volatile
End Period Cash Flow36.5 M22.8 M36 M
Slightly volatile
Sale Purchase Of Stock670.8 K706.1 K37.8 M
Pretty Stable
Net Borrowings494.7 K552.1 K477.9 K
Slightly volatile
Change To Netincome15.8 M11.6 M13.3 M
Slightly volatile
Issuance Of Capital Stock4.2 M4.4 M100.3 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio6.877.23611
Slightly volatile
Days Sales Outstanding2.392.5256.7432
Slightly volatile
Average Payables1.2 M2 M1.8 M
Slightly volatile
Stock Based Compensation To Revenue1.10.820.9565
Pretty Stable
Capex To Depreciation0.480.512.5736
Pretty Stable
EV To Sales4.24.42605
Slightly volatile
Days Of Inventory On Hand7.0E-47.0E-42.0E-4
Slightly volatile
Payables Turnover10095.4721.4418
Slightly volatile
Sales General And Administrative To Revenue1.942.882.2373
Slightly volatile
Average Inventory0.440.570.4694
Pretty Stable
Research And Ddevelopement To Revenue4.586.145.3872
Slightly volatile
Capex To Revenue0.03040.0320.0965
Very volatile
Cash Per Share17.0732.7211.2298
Slightly volatile
Days Payables Outstanding3.763.965.3 K
Slightly volatile
Current Ratio2.923.079.6804
Slightly volatile
Receivables Turnover15715047.8738
Slightly volatile
Capex Per Share0.05260.05010.0307
Slightly volatile
Revenue Per Share1.481.410.8323
Slightly volatile
Interest Debt Per Share0.560.595.8595
Slightly volatile
Debt To Assets0.01870.01970.4457
Slightly volatile
Operating Cycle2.392.5256.6063
Slightly volatile
Days Of Payables Outstanding3.763.965.3 K
Slightly volatile
Ebt Per Ebit1.031.09200.6 K
Slightly volatile
Quick Ratio2.923.079.6804
Slightly volatile
Net Income Per E B T0.620.90.8256
Slightly volatile
Cash Ratio0.550.585.7736
Slightly volatile
Days Of Inventory Outstanding7.0E-47.0E-42.0E-4
Slightly volatile
Days Of Sales Outstanding2.392.5256.7432
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.081.140.991
Pretty Stable
Fixed Asset Turnover2.873.028.1887
Slightly volatile
Debt Ratio0.01870.01970.4457
Slightly volatile
Price Sales Ratio6.877.23611
Slightly volatile
Asset Turnover0.06930.04710.0663
Pretty Stable

Assembly Biosciences Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap38.5 M40.5 M2.3 B
Very volatile
Enterprise Value23.5 M24.8 M2.3 B
Very volatile

Assembly Fundamental Market Drivers

Cash And Short Term Investments130.2 M

Assembly Upcoming Events

27th of March 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Assembly Biosciences Financial Statements

Assembly Biosciences stakeholders use historical fundamental indicators, such as Assembly Biosciences' revenue or net income, to determine how well the company is positioned to perform in the future. Although Assembly Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Assembly Biosciences' assets and liabilities are reflected in the revenues and expenses on Assembly Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Assembly Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue35.6 M37.3 M
Total Revenue8.2 M11.2 M
Cost Of Revenue56.2 M59 M
Stock Based Compensation To Revenue 0.82  1.10 
Sales General And Administrative To Revenue 2.88  1.94 
Research And Ddevelopement To Revenue 6.14  4.58 
Capex To Revenue 0.03  0.03 
Revenue Per Share 1.41  1.48 
Ebit Per Revenue(10.38)(10.90)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
CRMSalesforce
CRMSalesforce
When determining whether Assembly Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Assembly Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Assembly Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Assembly Biosciences Stock:
How To Invest In Assembly
Details
Is Assembly Stock a good investment?
Details
What is Assembly Biosciences' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Assembly Biosciences Correlation against competitors.
For information on how to trade Assembly Stock refer to our How to Trade Assembly Stock guide.
You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Assembly Biosciences. If investors know Assembly will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Assembly Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(6.89)
Revenue Per Share
4.968
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.38)
Return On Equity
(1.21)
The market value of Assembly Biosciences is measured differently than its book value, which is the value of Assembly that is recorded on the company's balance sheet. Investors also form their own opinion of Assembly Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Assembly Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Assembly Biosciences' market value can be influenced by many factors that don't directly affect Assembly Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Assembly Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Assembly Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Assembly Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY